All In Biotech

Drug Trial Radar · NCT06775236

Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors

A Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of SYS6010 as a Monotherapy or in Combination With SYH2051 Compared to Investigator's Choice Chemotherapy in Patients With EGFR-Expressing Advanced Unresectable or Metastatic Solid Tumors, Including But Not Limited to Breast Cancer

Last checked: Nov 20, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 410 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

410

Planned (sponsor's estimate)

Start

Mar 20, 2025

Primary completion

Jun 15, 2027

Study completion Jan 15, 2028

Sponsor

Sponsor type
Industry
First posted
Jan 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study consists of two phases. Phase 1b and Phase 2. Phase 1b aims to evaluate the safety, tolerability, and preliminary efficacy of SYS6010 as a monotherapy and in combination with SYH2051, and to determine the recommended Phase 2 dose (RP2D) for subsequent Phase 2 studies. Phase 2 aims to assess the efficacy and safety of SYS6010 monotherapy or in combination with SYH2051 compared to investigator-selected chemotherapy in patients with EGFR-expressing, unresectable locally advanced or metastatic advanced breast cancer.

Conditions

  • Advanced Solid Tumors
  • Breast Cancer

Interventions

  • SYS6010 jnjectionDrug

    SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker

  • monotherapy chemotherapyDrug

    Investigator's choice of monotherapy chemotherapy (Eribulin, Capecitabine, Gemcitabine, Vinorelbine, or Taxanes.)

  • SYH2051 tabletsDrug

    SYH2051 is a Selective ATM protein kinase inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity(DLT) occurrence and incidenceTime frame: Up to approximately 3 months after the first participant is enrolled
  2. Adverse events (AE) occurrence and incidenceTime frame: Up to approximately 36 months after the first participant is enrolled
  3. Objective response rate (ORR) per RECIST v1.1Time frame: Up to approximately 36 months after the first participant is enrolled

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.